Bøger i Breaking Tolerance to Antibody-Mediated Immunotherapy serien

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies. Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistanceOffers potential underlying mechanisms by which cancer cells are either inherently resistant or become unresponsive to antibody treatmentDiscusses how to develop new targeted agents to underlie resistance in order to expand research on this field

T Cell Metabolism and Cancer Immunotherapy delves into the intricate regulation of T-cell immunity and tolerance. As research advances in cell-based therapies, the potential of engineered immune cells to treat cancers and other diseases is becoming increasingly evident due to their powerful capabilities. Additionally, the book offers valuable insights into developing and optimizing strategies for bacterium-based immunotherapies. Despite great advancement in immunotherapy such as adoptive T cell transfer-based regimen, the clinical outcomes remain less satisfactory due to a variety of factors that lessen its therapeutic efficacy. By determining the role and importance of T cell metabolism in the regulation of T lymphocytes that are related to the development and managements of aberrant immunity, T Cell Metabolism and Cancer Immunotherapy designs and develops novel and more effective strategies for improving regimens for patients with aberrant immunity. Within ten chapters the content not only reveals targets of T cell metabolism as critical determinants of immune regulation, but also uncovers unique therapeutic opportunities to improve immunotherapy through targeting T cell metabolism. This fills a significant gap in the knowledge of scientists working in the field of onco-immunology/immunotherapy, and students learning about T cells, metabolism, immunomodulation, and immunotherapy.